- Home
- LIVN
LIVN
LivaNova PLC
as 11-22-2024 4:00pm EST
| Founded: | 1987 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | N/A | IPO Year: | 1993 |
| Target Price: | $67.14 | AVG Volume (30 days): | 555.9K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.43 | EPS Growth: | 759.09 |
| 52 Week Low/High: | $42.75 - $64.48 | Next Earning Date: | 10-30-2024 |
| Revenue: | $1,241,739,000 | Revenue Growth: | 11.04% |
| Revenue Growth (this year): | 10.27% | Revenue Growth (next year): | 5.35% |
Stock Insider Trading Activity of LivaNova PLC (LIVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bianchi Francesco | LIVN | Director | Sep 11 '24 | Sell | $46.58 | 1,500 | $69,870.00 | 8,772 |
Latest LivaNova PLC News
LIVN Breaking Stock News: Dive into LIVN Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint
Business Wire
9 days ago
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
MedTech Dive
10 days ago
Livanova hits sleep apnea trial goals, plans FDA filing
TipRanks
10 days ago
Goldman Sachs Says Improving Growth Could Propel These 2 Stocks Higher
Argus Research
10 days ago
LIVN: What does Argus have to say about LIVN?
Simply Wall St.
11 days ago
Shareholders Will Be Pleased With The Quality of LivaNova's (NASDAQ:LIVN) Earnings
Business Wire
11 days ago
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
Zacks
16 days ago
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Compare LIVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LIVN LivaNova PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.